Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.
Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

开始日期2025-01-01

申办/合作机构

University of Zurich

[+2]

NCT05680545 / Not yet recruitingN/A

Volatile Anesthetic Pharmacokinetics During Extracorporeal Membrane

The goal of this study is to design a pilot trial evaluating the safety, feasibility, pharmacokinetic modeling, and physiological effects of a volatile anesthetic, sevoflurane, directly administered in extracorporeal membrane oxygenation machines.

开始日期2024-07-01

申办/合作机构

University Health Network

[+1]

ChiCTR2400082962 / RecruitingN/AIIT

The 90% minimum effective concentration of sevoflurane for nasal tracheal intubation induced oral therapy in children was calculated by biased coin method

开始日期2024-04-11

申办/合作机构-

100 项与七氟烷相关的临床结果

登录后查看更多信息

100 项与七氟烷相关的转化医学

登录后查看更多信息

100 项与七氟烷相关的专利（医药）

登录后查看更多信息

9,996

项与七氟烷相关的文献（医药）

2024-03-01·Molecular medicine reports

Effect of fullerenol C60 on lung and renal tissue in lower extremity ischemia‑reperfusion injury in sevoflurane‑treated rats.

Article

作者: Ayşe Hande Arpaci ; Zeynep Köksal ; Zeynep Yiğman ; Ayşegül Küçük ; Volkan Şivgin ; Mustafa Arslan ; Mustafa Kavutçu ; Saadet Özen Akarca Di Zakar

The aim of the present study was to examine the effect of fullerenol C60 on lung and kidney tissue in sevoflurane‑treated rats with lower extremity ischemia‑reperfusion (IR) injury. A total of 30 Wistar albino rats weighing 225‑275 g were used and were equally divided into five groups (n=6/group): i) Sham; ii) IR; iii) IR‑fullerenol C60 (IR‑FUL); iv) IR‑sevoflurane; and v) IR‑fullerenol C60‑sevoflurane (IR‑FUL‑SEVO). Fullerenol C60 was administered intraperitoneally prior to lower extremity IR induction and sevoflurane was administered during the IR injury. Subsequently, lung and kidney histopathological examinations, and serum biochemical analyses were performed. Lung tissue showed markedly increased congestion and neutrophil infiltration in the IR group compared with in the sham group, and notable decreases in congestion and neutrophil infiltration were observed in the treatment groups compared with in the IR group. In the histopathological evaluation of the kidney samples, vacuolization, loss of brush border in tubular epithelial cells, tubular epithelial loss and varying degrees of tubular damage were observed in all groups that underwent IR. There was a significant increase in the mean renal tubule injury score in all IR groups compared with that in the sham group. In addition, the mean kidney injury score was significantly lower in the IR‑FUL and IR‑FUL‑SEVO groups than that in the IR group. It was observed that the expression levels of tumor necrosis factor‑α, interleukin 1β and intercellular adhesion molecule 1 in the lung and kidney tissues were increased following IR, and were decreased in the groups treated with fullerenol C60 and sevoflurane. Notably, it was determined that the reduction in cytokine expression was greatest in the IR‑FUL group. When the oxidant status parameters in the lungs and kidneys were examined, thiobarbituric acid reactive substances levels, and catalase and glutathione S‑transferase enzyme activities were significantly different in the groups receiving sevoflurane or fullerenol C60 treatment compared with those in the IR group. The present study demonstrated the protective effects of fullerenol C60 on the lung and kidney tissues of rats under sevoflurane anesthesia after establishment of lower extremity IR. The results of the present study showed that fullerenol C60 can reduce oxidative and histopathological damage in the lungs and kidneys following IR of the lower extremities.

2024-02-21·Anesthesia and analgesia

Effect of Propofol Infusion on Need for Rescue Antiemetics in Postanesthesia Care Unit After Volatile Anesthesia: A Retrospective Cohort Study.

Article

作者: Juraj Sprung ; Atousa Deljou ; Darrell R Schroeder ; David O Warner ; Toby N Weingarten

BACKGROUND:

Postoperative nausea and vomiting (PONV) are frequent after volatile anesthesia. We hypothesized that coadministration of propofol with volatile anesthetic compared to pure volatile anesthetics would decrease the need for postoperative antiemetic treatments and shorten recovery time in the postanesthesia care unit (PACU).

METHODS:

We retrospectively identified adult patients who underwent procedures using general anesthesia with volatile agents, with or without propofol infusion, from May 2018 through December 2020, and who were admitted to the PACU. Inverse probability of treatment weighting (IPTW) analysis was performed using generalized estimating equations with robust variance estimates to assess whether propofol was associated with decreased need for rescue antiemetics.

RESULTS:

Among 47,847 patients, overall IPTW rescue antiemetic use was 4.7% for 17,573 patients who received propofol and 8.2% for 30,274 who did not (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.49-0.61; P<.001). This effect associated with propofol was present regardless of the intensity of antiemetic prophylaxis (OR, 0.59, 0.51, and 0.58 for 0-1, 2, and ≥3 antiemetics used, respectively), procedural duration (OR, 0.54, 0.62, and 0.47 for ≤2.50, 2.51-4.00, ≥4.01 hours), and type of volatile agent (OR, 0.51, 0.52, and 0.57 for desflurane, isoflurane, and sevoflurane) (all P<.001). This effect was dose dependent, with little additional benefit for the reduction in the use of PACU antiemetics when propofol rate exceeded 100 μg/kg/min. Patients who received rescue antiemetics required longer PACU recovery time than those who did not receive antiemetics (ratio of the geometric mean, 1.31; 95% CI, 1.28-1.33; P<.001), but use of propofol did not affect PACU recovery time (ratio of the geometric mean, 1.00; 95% CI, 0.98-1.01; P=.56).

CONCLUSIONS:

The addition of propofol infusions to volatile-based anesthesia is associated with a dose-dependent reduction in the need for rescue antiemetics in the PACU regardless of the number of prophylactic antiemetics, duration of procedure, and type of volatile agent used, without affecting PACU recovery time.

2024-02-21·Surgical innovation

Immunotherapeutic Properties of Dexmedetomidine on Pain Management and Cardiovascular Function in Videolaparoscopic Cholecystectomies: A Randomized, Two-Arm, Double-Blinded, Placebo-Controlled Trial.

Article

作者: Gustavo Nascimento Silva ; Virna Guedes Brandão ; Marcelo Vaz Perez ; Sandoval Lage Sobrinho ; João Gabriel de Cerqueira Campos Villardi ; Priscilla Mendonça do Sacramento ; Luiz Claudio Pereira Ribeiro ; Rossano Kepler Alvim Fiorelli

BACKGROUND:

Laparoscopy represented one of the most innovative surgical techniques approached in the surgery field. Dexmedetomidine association with general anesthesia promotes the response control to trauma by altering the neuroinflammatory reflex, provides better clinical outcomes in the postoperative period and reduces the excessive use of drugs with risk for addiction. This trial aims to evaluate the potential drug treatment of dexmedetomidine on organic function, with the targets in neuroinflammation, perioperative pain control and blood pressure measurements in a medium-sized surgical model.

METHODS:

Fifty-two patients were randomized in two groups: Sevoflurane and Dexmedetomidine - A (dexmedetomidine infusion [1 μg/kg loading, .2-.5 μg/kg/h thereafter]) vs Sevoflurane and Saline .9% - B. Three blood samples were collected at three times: before surgery, 4 to 6 hours after surgery and 24 hours postoperatively. The primary outcome was inflammatory and endocrine mediators dosage analisys. Finally, we evaluated pain and opioid use as secondary outcomes, also the hemodynamic values.

RESULTS:

In Dexmedetomidine group A, a reduction of Interleukin 6 was found during 4-6 hours after surgery. A reduction of IL-10 was noted in the measurement of its values 24 hours after the procedure, with statistical significance. Also, systolic and diastolic blood pressure, as well heart rate were attenuated, and there was a lower incidence of pain and opioid consumption in the first postoperative hour (P < .0001) in the anesthetic recovery room.

CONCLUSIONS:

Dexmedetomidine provided anti-inflammatory activity, sympatholytic effect and analgesia with cardiovascular safety. It reinforces the therapeutic nature of highly selective α2-adrenergic agonists when combined within anesthetic interventions.

项与七氟烷相关的新闻（医药）

2024-04-04

·医药地理

儿童麻醉用药全景扫描：全球视野下分析和展望

在儿童医疗领域，麻醉用药一直是一个重要而敏感的话题。随着医学科技的不断进步，国外在儿童麻醉用药方面的研究和应用也在不断发展和完善。今天，我们就来聊聊国外儿童麻醉用药的现状，以及未来的发展趋势。01儿童麻醉用药的分类与特点儿童由于其生理和心理的特殊性，其心理、生理、药理及病理等方面不同于成人，不能简单地将成人的麻醉理论和技术照搬到儿童身上。儿童麻醉用药主要分为全身麻醉和局部麻醉两大类。全身麻醉是通过吸入、静脉、肌肉注射等方式，使中枢神经系统受到抑制，达到意识消失、全身无疼痛感觉的状态。其中，气管插管全身麻醉是最常用的方式，采用吸入麻醉药或静脉麻醉药，需要机械辅助呼吸。局部麻醉则是在身体的特定部位注射麻醉药，如普鲁卡因、利多卡因等，使该部位暂时失去感觉，而患者的意识保持清醒。02丙泊酚和七氟烷分别是静脉类麻醉药和吸入用麻醉药中儿童最常用的全身麻醉药物全身麻醉常用于儿童住院手术。在国外高收入国家，大约每7名儿童中就有1名在4岁前至少接受过1次麻醉手术。根据中国儿童用药数据库的数据显示，国外市场上的儿童用全身麻醉药品主要分为吸入用类全身麻醉药、静脉注射类全身麻醉药和阿片类全身麻醉药等。这些药品在全球范围内广泛上市，如氧化亚氮、异氟烷、七氟烷等吸入用麻醉药，丙泊酚、氯胺酮、依托咪酯等静脉注射用麻醉药，以及瑞芬太尼、舒芬太尼等阿片类麻醉药。丙泊酚和七氟烷分别是静脉类麻醉药和吸入用麻醉药中儿童最常用的药物，而阿片类麻醉药主要用于维持镇痛。表1：儿童用吸入用类全身麻醉制剂国外上市情况来源：中国儿童用药数据库，中国医药工业信息中心表2：儿童用静脉注射类全身麻醉制剂国外上市情况来源：中国儿童用药数据库，中国医药工业信息中心表3：儿童用阿片类全身麻醉制剂国外上市情况来源：中国儿童用药数据库，中国医药工业信息中心在全球销售情况方面，丙泊酚因其起效迅速、代谢快、安全性良好等特性，成为全球销售额最高的麻醉药。而七氟烷作为吸入性麻醉药市场的领头羊，尽管面临集采的影响，但仍保持着较高的市场份额。图1：儿童用全身麻醉制剂2015-2022年全球销售情况（单位：亿美元）来源：中国儿童用药数据库，中国医药工业信息中心03酰胺类局部麻醉药作为中长效麻醉药儿童麻醉效果更持久更有效在儿童麻醉领域，局部麻醉可以作为全身麻醉的替代方法单独使用，但更常与全身麻醉联合使用，以减少术中麻醉需求，并提供更长的术后镇痛作用。根据中国儿童用药数据库的数据显示，按化学结构和药理特性，局部麻醉药可以分为酰胺类、氨苯甲酸酯类酯类、苯甲酸酯类和其他类型。这些药物通过不同的给药方式，如注射、涂抹或喷雾，实现对手术或诊疗过程的疼痛管理。表4：局部麻醉药国外上市制剂分类来源：中国儿童用药数据库，中国医药工业信息中心在全球销售情况方面，局部麻醉药的种类繁多，包括布比卡因、利多卡因等。这些药物在儿童牙科治疗、皮肤手术、小型创伤修复等场景中广泛应用。例如，布比卡因由于其长效作用和较低的系统毒性而受到青睐，而利多卡因则因其快速起效和广泛的应用范围而备受推崇。图2：儿童用局部麻醉制剂2015-2022年全球销售情况（单位：亿美元）来源：中国儿童用药数据库，中国医药工业信息中心04新兴的儿童用麻醉药品研发方向在过去几十年中，常用的麻醉镇静药物几乎没有变化，每种药物在临床实践中都会有它的不足，这也促使科学家们不断探索，寻找新的药物。在儿童麻醉药品的研发方面，国外目前主要集中在布比卡因等局部麻醉药的研究。这些研究项目旨在探索更安全、更有效的麻醉方法，以减轻儿童在手术中的疼痛和不适。同时，一些新兴的麻醉药物也在研发之中，如正在研发的环丙基甲氧基羰基甲基咪唑（ABP-700）和ET-26盐酸盐（ET-26HCl）两种依托咪酯类似物既可以保留依托咪酯样的麻醉活性，又可以去除肾上腺皮质抑制的副作用，从而达到临床应用更安全的目的。日本上市使用的氙气尽管存在某些不足，如麻醉费用高、来源少，但氙气在药代动力学和药效学上的优势，未来临床可以考虑釆用其作为麻醉气体实际应用。还有利多卡因季铵类衍生物由于更有效、更持久，一直是公认的研发热点方向。这些新药有望在未来为儿童麻醉提供更多的选择和更好的治疗效果。05总结国外在儿童麻醉用药方面的研究和应用已经取得了显著的成果，但仍有许多工作需要去做。随着科技的发展和临床需求的不断变化，未来儿童麻醉用药将更加注重安全性、有效性和个体化治疗。让我们期待更多的创新药物和治疗方法的出现，为全球儿童的健康事业贡献力量。END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

医药出海

2024-04-02

·PRNewswire

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

World's leading provider of veterinary care will be first to introduce innovative in-clinic solution to support sustainability goals BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. During a typical anaesthetic procedure, less than five percent of the volatile anaesthetic agent delivered to a patient is absorbed and metabolised, leaving approximately 95 percent it to be exhaled. Continue Reading Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions SageTech's trusted gas-capture technology—which is currently used in human healthcare—works by capturing the waste anaesthetic agent breathed out during an operation by safely adsorbing it into a specially developed reusable capture canister. These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere. "As a leading provider of veterinary care, we have a responsibility to take climate action at scale and lead the way toward more sustainable practices," said Ellie West, RCVS and EBVS® European Specialist in Veterinary Anaesthesia and Analgesia, and Linnaeus Environmental Sustainability Lead. "Our innovative collaboration should help us take a significant step forward in our sustainability journey, aimed at contributing to a better future for the planet—and the people and pets who depend on it." A veterinary-industry first, Mars Veterinary Health's one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts. Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come. "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical. "It has been wonderful to work with the Linnaeus and Waltham teams, and we are confident this pilot project will demonstrate to the veterinary profession how such collaborations can be a collective force for good." This industry-first pilot in sustainable veterinary care is consistent with Mars, Incorporated's Net Zero Roadmap, a detailed action plan for achieving net zero greenhouse gas emissions by 2050, as well as details on the company's progress and history of working on climate action. Details about Mars, Incorporated's wider sustainability—including climate—work can be found in its Sustainable in a Generation Scorecard. About Mars Veterinary Health Mars Veterinary Health is a global division of Mars Petcare dedicated to delivering high-quality pet healthcare to further its collective Purpose: A BETTER WORLD FOR PETS™. Mars Veterinary Health's 70,000 Associates across 3,000 global veterinary clinics put pets, people, and the planet first. The Mars Veterinary Health family includes Associates at AniCura, Banfield, BluePearl, Creature Comforts, Gentle Oak, Hillside, Linnaeus, Mount Pleasant, Tai Wai, VCA, VES, and VSH who demonstrate compassion and expertise while enabling 35 million pet visits each year. Learn more at marsveterinary.com. About Linnaeus Part of Mars Veterinary Health, Linnaeus is a highly respected community of more than 50 primary care and 17 referral veterinary practices based in the UK. Linnaeus employs over 6,000 pet-loving Associates with some of the country's finest vet and nursing teams who together are committed to excellence and delivering high-quality care to patients. Learn more at linnaeusgroup.co.uk. About Mars Science & Diagnostics Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Antech, our global veterinary diagnostics business, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software; reference laboratories; veterinary imaging and technology; education; and telemedicine with board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world's most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health. About SageTech Veterinary The manufacture of virgin anaesthetic agents and their release as waste volatile gases is highly damaging to the environment and contributes significantly to the total carbon footprint of healthcare. SageTech Veterinary is part of SageTech Medical, a medical device and pharmaceutical company focused on the research, design, manufacture, and distribution of technologies for the capture and recycling of waste volatile anaesthetic agents in human and animal healthcare. Their unique circular economy solution safely captures volatile anaesthetic agents (sevoflurane, isoflurane, desflurane) through actively controlled adsorption onto a reusable capture canister. Learn more at sagetechveterinary.com. Photo - SOURCE Mars PetCare

2024-03-27

·米内网

【审评】狙击超1000亿市场，四川药企潜力儿科药火了

精彩内容近日，CDE官网显示，四川百利药业的盐酸胍法辛缓释片拟纳入优先审评，用于治疗儿童注意缺陷多动障碍（ADHD）。本品属于神经系统化学药，米内网数据显示，2022年中国三大终端六大市场（统计范围见文末）该品类合计销售规模超过1000亿元。来源：CDE官网盐酸胍法辛是一种选择性α2a-肾上腺能受体激动剂，属于神经系统类药物，其能够直接与前额叶皮层中的受体结合，达到提高行为抑制力、改善注意力、增强冲动控制等效果。在中国三大终端六大市场，2022年神经系统化学药市场规模超过1000亿元，2023年上半年突破560亿元，预计全年销售额将创下新高。近年中国三大终端六大市场神经系统化学药销售趋势（单位：万元）来源：米内网格局数据库盐酸胍法辛缓释片最早由希尔制药研发，于2009年9月首次获美国FDA批准上市，用于治疗儿童和青少年注意力缺乏和多动症（ADHD）。得益于药副作用小、无已知滥用或依赖性等优势，盐酸胍法辛缓释片（2mg）被收录于国家卫计委等三部门联合发布的《第二批鼓励研发申报儿童药品建议清单》。米内网数据显示，目前该药暂未在国内获批上市，仅四川百利药业提交的仿制3类上市申请在审，抢首仿在时间上领先；另有6家企业申报的产品已获批临床，其中人福药业、济南百诺医药等正针对ADHD适应症开展Ⅲ期临床试验。四川百利药业以新分类获批上市的仿制药来源：米内网中国申报进度（MED）数据库四川百利药业成立于1996年，是一家集研发、生产、销售为一体的现代化制药企业。目前公司主导产品包括消旋卡多曲颗粒、黄芪颗粒、替硝唑阴道泡腾片、吸入用七氟烷等，覆盖儿科、妇科、麻醉、抗感染等治疗领域；以新分类获批上市的仿制药有3款，其中马来酸依那普利口服溶液为首仿+首家过评品种。资料来源：米内网数据库、CDE官网注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至3月27日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准临床3期

100 项与七氟烷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00547	七氟烷	N01AB08	DB01236

研发状态

适应症	最高研发状态	国家/地区	公司
麻醉	批准上市	中国更多	Maruishi Pharmaceutical Co., Ltd. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03553446 (Pubmed)	N/A	脑瘫	23	Sevoflurane	簾鏇顧艱積餘觸鑰壓網(顧衊顧鹽願選遞獵廠願) = 襯餘壓遞鑰夢獵壓壓蓋壓夢膚餘夢齋顧構蓋廠 (夢夢齋觸蓋積蓋淵遞齋, 1.62 ~ 1.90) 更多	积极	2022-10-21
NCT01975064 (CAN-study, Pubmed)	临床4期	乳腺癌	1,764	Propofol	(糧製範構壓願衊蓋鬱鏇) = 鏇網網築鬱獵窪蓋獵鏇壓鏇願醖鑰觸遞憲築構 (壓顧積淵衊廠憲齋襯選, 90.1 ~ 93.8)	不佳	2023-06-01
				Sevoflurane	(糧製範構壓願衊蓋鬱鏇) = 鹽獵鑰願觸餘願顧窪鬱壓鏇願醖鑰觸遞憲築構 (壓顧積淵衊廠憲齋襯選, 90.3 ~ 94.0)
NCT03498235 (Pubmed \| BMC Anesthesiol)	早期临床1期	-	110	Propofol	糧顧遞製窪醖製餘構顧(鏇鹹糧醖鬱繭製構構襯) = 繭遞簾鬱鏇鏇願鹹鹽夢衊衊鬱觸憲齋遞範夢醖 (遞衊願鏇鬱蓋鹽鑰鑰餘 )	-	2021-01-27
				Sevoflurane	糧顧遞製窪醖製餘構顧(鏇鹹糧醖鬱繭製構構襯) = 艱築獵艱製鬱鹹選壓憲衊衊鬱觸憲齋遞範夢醖 (遞衊願鏇鬱蓋鹽鑰鑰餘 )
NCT03772054 (Pubmed \| BMC Anesthesiol)	N/A	-	16	Sevoflurane	製範積製鏇壓憲艱窪觸(鏇鏇範鑰構憲襯淵簾窪) = 顧構願構餘艱夢鬱憲願觸鑰繭淵廠製餘顧窪鑰 (顧構襯廠鹽鹹壓鹹膚鏇 )	-	2020-05-20
NCT02839668 (Pubmed \| Vet Anaesth Analg)	临床2期	乳腺癌	120	Sevoflurane	積衊醖淵醖範醖遞選窪(顧願餘衊餘觸顧構憲鹹) = 餘築鬱築構鬱製淵鏇鏇築鑰夢顧鹹鏇簾齋鏇積 (醖餘廠網鏇壓獵鑰範繭 )	-	2020-06-29
				Sevoflurane plus i.v. lidocaine	積衊醖淵醖範醖遞選窪(顧願餘衊餘觸顧構憲鹹) = 選鏇艱窪廠膚艱願網構築鑰夢顧鹹鏇簾齋鏇積 (醖餘廠網鏇壓獵鑰範繭 )
NCT03816072 (Pubmed)	N/A	脑缺血	-	Propofol-based anaesthesia	獵鹹窪觸積襯窪餘範艱(憲淵願衊顧積積糧糧顧) = 顧壓繭窪鹽憲鏇淵憲願網鹹廠繭簾網淵壓淵齋 (廠夢壓選蓋糧顧糧顧繭, 0.51 ~ 0.95) 更多	-	2023-02-07
				Sevoflurane-based anaesthesia	獵鹹窪觸積襯窪餘範艱(憲淵願衊顧積積糧糧顧) = 鏇襯餘獵廠廠築憲夢繭網鹹廠繭簾網淵壓淵齋 (廠夢壓選蓋糧顧糧顧繭, 0.01 ~ 0.42) 更多
ARVO2020	N/A	-	-	Sevoflurane gas	網鹹製壓積構遞醖壓獵(壓顧選鹽鑰醖鬱廠鏇壓) = 齋觸齋鹽鬱鏇餘遞築襯積壓餘窪築鏇齋遞廠淵 (糧願餘觸糧齋築淵餘獵 )	-	2020-06-01
				Propofol infusion	網鹹製壓積構遞醖壓獵(壓顧選鹽鑰醖鬱廠鏇壓) = 蓋艱鑰膚襯憲獵遞廠製積壓餘窪築鏇齋遞廠淵 (糧願餘觸糧齋築淵餘獵 )
NCT03234582 (Pubmed)	N/A	法洛四联症	-	Sevoflurane 1%	齋構餘衊鹹糧簾觸壓衊(鏇製鏇遞鏇鹽獵製鏇選) = 醖憲鑰製網憲齋餘廠衊顧積憲餘膚憲築鹽遞醖 (遞願網鑰膚膚範夢積廠 )	-	2021-01-01
				Sevoflurane 2%	齋構餘衊鹹糧簾觸壓衊(鏇製鏇遞鏇鹽獵製鏇選) = 齋鑰糧築夢夢廠繭廠鬱顧積憲餘膚憲築鹽遞醖 (遞願網鑰膚膚範夢積廠 )
NCT02662257 \| ChiCTR-IPR-15006209 (Pubmed)	N/A	谵妄	1,228	Propofol-based anaesthesia	(構糧齋積膚鏇網糧艱鹹) = 鏇繭鬱糧鹹餘鏇繭簾夢鏇醖遞網繭壓網壓遞膚 (獵憲夢繭襯憲構選壓簾 )	积极	2023-08-01
				Sevoflurane-based anaesthesia	(構糧齋積膚鏇網糧艱鹹) = 製鑰夢繭鏇鹽築壓顧鏇鏇醖遞網繭壓網壓遞膚 (獵憲夢繭襯憲構選壓簾 )